Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04565054
Title Adj. Dyn. Marker-adjusted Personalized Therapy Comparing Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC (ADAPTlate)
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors West German Study Group
Indications

Her2-receptor negative breast cancer

Therapies

Abemaciclib

Tamoxifen

Age Groups: adult | senior
Covered Countries DEU


No variant requirements are available.